Adjuvant Therapy

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

By

The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

By

Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.

Adjuvant Therapy Improves Survival in Stage II Colon Cancer, Study Confirms

By

A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.

Adjuvant CRT Feasible for High-risk Endometrial Cancer

By

Adjuvant chemotherapy administered during and after radiotherapy is feasible for the treatment of patients with high-risk endometrial cancer despite an increased risk of toxicities compared with radiotherapy alone.

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

By

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

By

In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

By

Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy.

Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer

Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer

By

The accuracy of axillary staging and of pathologic evaluation of clinically node-positive breast cancer is improved by a new procedure, reducing the need for a more invasive procedure with debilitating complications.

Breast Cancer Adjuvant Therapy Benefit Can Wax and Wane Over Time

By

Women are prescribed adjuvant therapies after breast cancer surgery to reduce the risk of cancer recurrence. The effects of these therapies have been assumed to remain constant over time, but a new study suggests the opposite is true.

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

By

Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.

Breast cancer tumor response to neoadjuvant chemotherapy (NAC) measured

By

Diffuse optical spectroscopic tomographic imaging (DOST) may be useful in predicting which patients will best respond to chemotherapy used to reduce breast cancer tumors before surgery, according to a new study.

Trastuzumab shows benefit years after treatment for HER2+ breast cancer

By

The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

Cediranib added to chemotherapy improves progression-free survival in cervical cancer

By

Addition of the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival for patients with cervical cancer that has recurred after treatment.

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

By

Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.

Irinotecan promising in some patients with stage III colon cancer

By

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to recent research.

Protein is predictive of treatment that makes radiotherapy for bladder cancer more effective

By

Scientists have identified a protein that could help doctors decide which patients with bladder cancer would benefit from a treatment that makes radiotherapy more effective, according to a new study.

Chemotherapy not routine for high-risk bladder cancer yet improves survival

By

Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice.

Vitamin D increases survival for breast cancer patients

Vitamin D increases survival for breast cancer patients

By

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease, according to a recent meta-analysis.

Sequential gemtuzumab ozogamicin and chemotherapy not beneficial for older patients with AML

By

Sequentially combining gemtuzumab ozogamicin and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia.

Adjuvant and Neoadjuvant Therapy for Breast Cancer (Fact Sheet)

This fact sheet defines adjuvant therapy for breast cancer and explains the length of treatment, which patients are best suited for this treatment, side effects, and highlights current research.

Epoetin alfa reduces anemia but raises clot risk in breast cancer

By

Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.

Many children with retinoblastoma can safely forego adjuvant chemotherapy

By

A prospective clinical trial conducted in France found that children with low-risk retinoblastoma do not need adjuvant chemotherapy to prevent disease recurrence or metastasis.

Extending treatment with adjuvant trastuzumab provided no additional benefit

By

Patients with early-stage HER2-positive breast cancer should still receive 1 year of adjuvant trastuzumab as the standard of care, according to data from the phase III HERA trial.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Trastuzumab raises heart risk in older women with breast cancer

Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.

A clearer role for radiotherapy in high-risk melanoma

A clearer role for radiotherapy in high-risk melanoma

By

A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.

Older women okay without hormone therapy for early breast cancer

Women 60 years and older who received no systemic adjuvant therapy for early-stage breast tumors were at no greater mortality risk than similarly aged women in the general population.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs